Insider Trading Alert - CODE, COV And STXS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 8, 2014, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $294.00 to $12,417,450.00.

Highlighted Stocks Traded by Insiders:

Spansion (CODE) - FREE Research Report

Wishart Michael S, who is Director at Spansion, sold 666 shares at $28.85 on Dec. 8, 2014. Following this transaction, the Director owned 5,657 shares meaning that the stake was reduced by 10.53% with the 666-share transaction.

The shares most recently traded at $29.85, up $1.00, or 3.35% since the insider transaction. Historical insider transactions for Spansion go as follows:

  • 4-Week # shares sold: 2,208
  • 12-Week # shares sold: 3,958
  • 24-Week # shares sold: 29,640

The average volume for Spansion has been 2.2 million shares per day over the past 30 days. Spansion has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are up 113.97% year-to-date as of the close of trading on Monday.

Spansion, Inc. designs, manufactures, develops, and sells embedded systems semiconductors worldwide. The company offers flash memory, microcontrollers, mixed-signal and analog products, and embedded system-on-chip solutions. Currently, there are 5 analysts who rate Spansion a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CODE - FREE

TheStreet Quant Ratings rates Spansion as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and robust revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Spansion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien (COV) - FREE Research Report

Sgrignari Michael, who is Senior Vice President at Covidien, sold 25,795 shares at $103.48 on Dec. 8, 2014. Following this transaction, the Senior Vice President owned 10,724 shares meaning that the stake was reduced by 70.63% with the 25,795-share transaction.

The shares most recently traded at $102.31, down $1.17, or 1.15% since the insider transaction. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares bought: 5,921
  • 4-Week # shares sold: 3,464
  • 12-Week # shares bought: 5,921
  • 12-Week # shares sold: 7,464
  • 24-Week # shares bought: 16,518
  • 24-Week # shares sold: 7,464

The average volume for Covidien has been 4.9 million shares per day over the past 30 days. Covidien has a market cap of $46.9 billion and is part of the health care sector and health services industry. Shares are up 52.25% year-to-date as of the close of trading on Monday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. The stock currently has a dividend yield of 1.39%. The company has a P/E ratio of 28.4. Currently, there are 5 analysts who rate Covidien a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Stereotaxis (STXS) - FREE Research Report

Mills William C. III, who is Chief Executive Officer at Stereotaxis, bought 10,000 shares at $1.43 on Dec. 8, 2014. Following this transaction, the Chief Executive Officer owned 229,711 shares meaning that the stake was boosted by 4.55% with the 10,000-share transaction.

The shares most recently traded at $1.56, up $0.13, or 8.33% since the insider transaction. Historical insider transactions for Stereotaxis go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 15,809
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 15,809
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 15,809

The average volume for Stereotaxis has been 84,800 shares per day over the past 30 days. Stereotaxis has a market cap of $29.5 million and is part of the health care sector and health services industry. Shares are down 59.67% year-to-date as of the close of trading on Monday.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. The company has a P/E ratio of 3.1. Currently, there are no analysts who rate Stereotaxis a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STXS - FREE

TheStreet Quant Ratings rates Stereotaxis as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Stereotaxis Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: Shark Tank Star Kevin O'Leary on Netflix, Amazon and Trade Worries

Video: Shark Tank Star Kevin O'Leary on Netflix, Amazon and Trade Worries

Bank of America Up 3.9% on Earnings Beat, But Analysts See Even More Gains Ahead

Bank of America Up 3.9% on Earnings Beat, But Analysts See Even More Gains Ahead

Microsoft's Growing Public Cloud Is Exciting: Morgan Stanley

Microsoft's Growing Public Cloud Is Exciting: Morgan Stanley

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings